{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:29:01Z","timestamp":1765700941693,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.anl.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T08:44:37Z","timestamp":1558601077000},"page":"116-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Outcome of chemotherapy following nivolumab treatment for recurrent and\/or metastatic head and neck squamous cell carcinoma"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-9162","authenticated-orcid":false,"given":"Takahiro","family":"Wakasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Yasumatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Uchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Taura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mioko","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritaka","family":"Komune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2019.05.001_bib0005","first-page":"1149","article-title":"Stress-triggered atavistic reprogramming (STAR) addiction: driving force behind head and neck cancer?","volume":"6","author":"Masuda","year":"2016","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.anl.2019.05.001_bib0010","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2019.05.001_bib0015","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2019.05.001_bib0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12032-018-1096-5","article-title":"Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review","volume":"35","author":"Guidi","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.anl.2019.05.001_bib0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.anl.2019.05.001_bib0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer","volume":"13","author":"Park","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.anl.2019.05.001_bib0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2017.08.022","article-title":"Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer","volume":"73","author":"Szabados","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.anl.2019.05.001_bib0040","doi-asserted-by":"crossref","first-page":"91795","DOI":"10.18632\/oncotarget.20030","article-title":"Excellent response to chemotherapy post immunotherapy","volume":"8","author":"Dwary","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.anl.2019.05.001_bib0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.oraloncology.2018.04.013","article-title":"Progression beyond nivolumab: stop or repeat? Dramatic responses with salvage chemotherapy","volume":"81","author":"Daste","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2019.05.001_bib0050","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.oraloncology.2016.10.020","article-title":"Immunotherapy in head and neck cancer: need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment","volume":"64","author":"Daste","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2019.05.001_bib0055","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/annonc\/mdr367","article-title":"Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck","volume":"23","author":"Hitt","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2019.05.001_bib0060","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.anl.2019.05.001_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.anl.2019.05.001_bib0070","doi-asserted-by":"crossref","DOI":"10.4161\/onci.25962","article-title":"Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment","volume":"2","author":"Kershaw","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.anl.2019.05.001_bib0075","doi-asserted-by":"crossref","DOI":"10.4161\/onci.25961","article-title":"Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy","volume":"2","author":"Devaud","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.anl.2019.05.001_bib0080","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/mt.2010.159","article-title":"Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms","volume":"18","author":"Fridlender","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.anl.2019.05.001_bib0085","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2326-6066.CIR-16-0333","article-title":"Increased PD-1(+) and TIM-3(+) TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients","volume":"5","author":"Jie","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.anl.2019.05.001_bib0090","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1158\/1078-0432.CCR-13-0035","article-title":"Merkel polyomavirus-specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers","volume":"19","author":"Afanasiev","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2019.05.001_bib0095","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.imbio.2016.04.005","article-title":"Tim-3 identifies exhausted follicular helper T cells in breast cancer patients","volume":"221","author":"Zhu","year":"2016","journal-title":"Immunobiology"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814618310484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814618310484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:35:33Z","timestamp":1759952133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814618310484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0385814618310484"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2019.05.001","relation":{},"ISSN":["0385-8146"],"issn-type":[{"type":"print","value":"0385-8146"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of chemotherapy following nivolumab treatment for recurrent and\/or metastatic head and neck squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}